Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - chlorantraniliprole; thiamethoxam - water dispersible granule - chlorantraniliprole benzene active 200.0 g/kg; thiamethoxam thiazole active 200.0 g/kg - insecticide - cotton - brokenbacked bug | cotton aphid | cotton budworm or bollworm | green mirid bug | green peach aphid | native budworm or bollworm | vegetable leafhopper | yellow mirid | apple dimpling bug | brokenback bug | corn earworm | cotton bollworm | dimpling bug | heliothis | melon aphid | native bollworm | taylorilygus apicalis | tobacco budworm | tomato grub | vegetable jassid

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sherwood corporation (thailand) public company limited - imidacloprid - suspension concentrate - imidacloprid guanidine active 200.0 g/l - insecticide - building - post construction | building construction | reticulation system | soil treatment of poles | termite nest or colony | - giant termite | subterranean termite ex. m. darwiniensis | coptotermes spp. | giant northern termite | schedorhinotermes spp.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

2022 environmental science au pty ltd - deltamethrin - laminated blanket - deltamethrin pyrethroid active 4.0 g/kg - insecticide - building construction | buildings - around | chemical soil barrier | chemical soil treatment zones | commercial, industrial | do - subterranean termite - coptotermes spp. | coptotermes acinaciformis | coptotermes frenchi | coptotermes lacteus

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - somatropin 12mg (41.4iu [13.8mg] with overage.) - powder for injection - 12 mg - active: somatropin 12mg (41.4iu [13.8mg] with overage.) excipient: dibasic sodium phosphate glycine mannitol monobasic sodium phosphate mannitol metacresol water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with genotropin miniquick is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - somatropin 5.3mg (18.4iu [6.1mg] with overage.) - powder for injection - 5.3 mg - active: somatropin 5.3mg (18.4iu [6.1mg] with overage.) excipient: dibasic sodium phosphate glycine mannitol monobasic sodium phosphate mannitol metacresol water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with genotropin miniquick is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - somatropin 5.8mg equivalent to 5 mg somatropin (after reconstitution) - powder for injection - 5 mg - active: somatropin 5.8mg equivalent to 5 mg somatropin (after reconstitution) excipient: dibasic sodium phosphate glycine mannitol monobasic sodium phosphate mannitol metacresol water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with genotropin miniquick is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 5.83 mg/ml - solution for injection - 5.83 mg/ml - active: somatropin 5.83 mg/ml excipient: citric acid phenol poloxamer sodium hydroxide sucrose water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8 mg/ml - solution for injection - 8 mg/ml - active: somatropin 8 mg/ml excipient: citric acid phenol poloxamer sodium hydroxide sucrose water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 3.33mg equivalent to 10 iu ((3 mg plus 10% overage)) - injection with diluent - 3 mg - active: somatropin 3.33mg equivalent to 10 iu ((3 mg plus 10% overage)) excipient: dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate monohydrate benzyl alcohol sodium chloride water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8.8mg ((includes 0.8 mg overfill)) - injection with diluent - 8 mg - active: somatropin 8.8mg ((includes 0.8 mg overfill)) excipient: phosphoric acid sodium hydroxide sucrose metacresol water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).